Skip to content

CytomX Therapeutics CTMX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$18.25M+31.2%-$26.51M-86.3%-$14.23M-9,140%-$154K-101%$23.53M+24.6%
$4.71M+218%$1.48M+6.9%$1.38M-3.3%$1.43M-28.7%$2.01M+6.6%
-$25.55M-9.9%-$23.24M-49.5%-$15.55M+1.3%-$15.75M+25.1%-$21.04M-5.7%
$0-100%$201K$27K-77.3%$119K+48.8%
-$192.78M-1,237%-$14.42M$0+100%-$76.36M-350%$30.6M+102%
$234.49M+1,309%$16.64M+6,478%$253K-99.7%$93.55M$0-100%
$16.16M+177%-$21.02M-41.5%-$14.86M-1,134%$1.44M-85.0%$9.55M
-$25.55M-9.0%-$23.44M-52.0%-$15.42M+2.3%-$15.78M+25.4%-$21.16M-5.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does CytomX Therapeutics generate?
CytomX Therapeutics (CTMX) generated -$80.1M in operating cash flow over the trailing twelve months.
What is CytomX Therapeutics's free cash flow?
After $347.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$80.2M over the trailing twelve months, up 1.7% year over year.
Where does CytomX Therapeutics's cash flow data come from?
Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.